Massive Bio Says AI Can Match Thousands of Cancer Patients to Clinical Trials at Scale

Clinical trial matching has long been a mismatch between need and capacity. Oncology teams know that many patients could benefit from a study, but manual review of eligibility criteria against records is slow, inconsistent, and often too dependent on a few specialists.

A prospective study is especially important here because it moves the conversation beyond retrospective hype. If AI can reliably sort through complex eligibility rules and identify plausible matches across thousands of patients, it could expand access to experimental therapies and improve trial enrollment efficiency.

But scale alone does not solve the hardest problems. Trial matching systems still need clean data, tight integration with clinical workflows, and a way to explain why a patient was or was not recommended. Without that, clinicians may not trust the output, and patients may never benefit.

The broader implication is that AI in oncology is becoming less about research novelty and more about operational throughput. In a field where access often depends on logistics, systems that reduce friction may be as valuable as systems that improve diagnostic accuracy.